Search Results - "Goodkin, D E"

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS by GHALIE, R. G, EDAN, G, LAURENT, M, MAUCH, E, EISENMAN, S, HARTUNG, H. P, GONSETTE, R. E, BUTINE, M. D, GOODKIN, D. E

“…Mitoxantrone (MITO) is associated with dose-related cardiotoxicity when administered concomitantly with other cytotoxic agents with or without radiotherapy for…”
Get full text

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis by Ghalie, R G, Mauch, E, Edan, G, Hartung, H P, Gonsette, R E, Eisenmann, S, Le Page, E, Butine, M D, Goodkin, D E

“…To evaluate the incidence of therapy-related acute leukaemia (t-AL) after single-agent mitoxantrone (MITO) treatment, we reviewed medical records of patients…”
Get full text

Psychological stress and the subsequent appearance of new brain MRI lesions in MS by MOHR, D. C, GOODKIN, D. E, BACCHETTI, P, BOUDEWYN, A. C, HUANG, L, MARRIETTA, P, CHEUK, W, DEE, B

“…To examine the relationship between stressful life events and psychological distress, and the subsequent development of gadolinium-enhancing (Gd+) brain…”
Get full text

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis by RUDICK, R. A, SIMONIAN, N. A, MASS, M. K, RICHERT, J. R, SALAZAR, A. M, MUNSCHBAUER, F. E, COOKFAIR, D. L, SIMON, J. H, JACOBS, L. D, ALAM, J. A, CAMPION, M, SCARAMUCCI, J. O, JONES, W, COATS, M. E, GOODKIN, D. E, WEINSTOCK-GUTTMAN, B, HERNDON, R. M

Get full text

A serial study of new MS lesions and the white matter from which they arise by GOODKIN, D. E, ROONEY, W. D, WEINER, M. W, SLOAN, R, BACCHETTI, P, GEE, L, VERMATHEN, M, WAUBANT, E, ABUNDO, M, MAJUMDAR, S, NELSON, S

“…To compare MS normal-appearing white matter (NAWM) where new gadolinium-enhancing (Gd+) lesions do and do not arise. A total of 22 relapsing-remitting MS…”
Get full text

Drugs used to treat spasticity by KITA, M, GOODKIN, D. E

“…Spasticity is a common and disabling symptom for many patients with upper motor neuron dysfunction. It results from interruption of inhibitory descending…”
Get full text

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis by Goodkin, D E, Rudick, R A, VanderBrug Medendorp, S, Daughtry, M M, Schwetz, K M, Fischer, J, Van Dyke, C

“…A randomized, double-blinded, placebo-controlled, clinical trial of low-dose, weekly, oral methotrexate was performed in 60 patients with clinically definite…”
Get more information

A longitudinal study of brain atrophy in relapsing multiple sclerosis by SIMON, J. H, JACOBS, L. D, SIMONIAN, N, LAJAUNIE, M, MILLER, D. E, WENDE, K, MARTENS-DAVIDSON, A, KINKEL, R. P, MUNSCHAUER, F. E, BROWNSCHEIDLE, C. M, CAMPION, M. K, RUDICK, R. A, COOKFAIR, D. L, HERNDON, R. M, RICHERT, J. R, SALAZAR, A. M, FISCHER, J. S, GOODKIN, D. E

Get full text

MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy by Pelletier, D, Nelson, S J, Oh, J, Antel, J P, Kita, M, Zamvil, S S, Goodkin, D E

“…Objectives: To investigate whether axonal damage in primary progressive (PP) multiple sclerosis (MS), as measured by proton magnetic resonance spectroscopy…”
Get full text

Side effect profile of interferon beta-1b in MS : Results of an open label trial by NEILLEY, L. K, GOODIN, D. S, GOODKIN, D. E, HAUSER, S. L

“…To determine which patients are prone to side effects from interferon beta-1b and which side effects are most troublesome, we studied 72 patients with…”
Get full text

A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis by GOODKIN, D. E, KINKEL, R. P, WEINSTOCK-GUTTMAN, B, VANDERBRUG MEDENDORP, S, SECIC, M, GOGOL, D, PERRYMAN, J. E, UCCELLI, M. M, NEILLEY, L

“…To compare the tolerability and efficacy of two doses of i.v. methylprednisolone in patients with secondary-progressive MS. I.v. methylprednisolone…”
Get full text

Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI) by BEATTY, W. W, PAUL, R. H, WILBANKS, S. L, HAMES, K. A, BLANCO, C. R, GOODKIN, D. E

“…Cognitive impairment affects 40 to 70% of patients with multiple sclerosis (MS), but its occurrence cannot be predicted from knowledge of the individual…”
Get full text

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis by RUDICK, R. A, GOODKIN, D. E, ALAM, J. J, SIMONIAN, N. A, CAMPION, M. K, BARTOSZAK, D. M, BOURDETTE, D. N, BRAIMAN, J, BROWNSCHEIDLE, C. M, COATS, M. E, COHAN, S. L, DOUGHERTY, D. S, JACOBS, L. D, KINKEL, R. P, MASS, M. K, MUNSCHAUER, F. E, PRIORE, R. L, PULLICINO, P. M, SCHEROKMAN, B. J, WEISTOCK-GUTTMAN, B, WHITHAM, R. H, COOKFAIR, D. L, HERNDON, R. M, RICHERT, J. R, SALAZAR, A. M, FISCHER, J. S, GRANGER, C. V, SIMON, J. H

Get full text

Overview of azathioprine treatment in multiple sclerosis by Yudkin, P L, Ellison, G W, Ghezzi, A, Goodkin, D E, Hughes, R A, McPherson, K, Mertin, J, Milanese, C

“…The efficacy of azathioprine in the treatment of multiple sclerosis was assessed by meta-analysis of the results of all published blind, randomised, controlled…”
Get more information

Interferon β therapy for multiple sclerosis by Goodkin, Donald E

Get full text

A longitudinal study of ventricular volume in early relapsing-remitting multiple sclerosis by Luks, T L, Goodkin, D E, Nelson, S J, Majumdar, S, Bacchetti, P, Portnoy, D, Sloan, R

“…The specific aim of this study was to determine whether progressive brain atrophy could be detected within 18 months of establishing a diagnosis of…”
Get full text

Low-dose oral methotrexate in chronic progressive multiple sclerosis : Analyses of serial MRIs by GOODKIN, D. E, RUDICK, R. A, VANDERBRUG MEDENDORP, S, DAUGHTRY, M. M, VAN DYKE, C

“…We monitored 56 patients with chronic progressive multiple sclerosis (MS) who participated in a clinical trial of weekly, low-dose oral methotrexate with…”
Get full text

T2 relaxation time histograms in multiple sclerosis by GRENIER, D, PELLETIER, D, NORMANDEAU, M, NEWITT, D, NELSON, S, GOODKIN, D. E, MAJUMDAR, S

“…An accurate measurement of the transverse relaxation time T(2), and the histogram of T(2) in the brain parenchyma can be accomplished in vivo using a…”
Get full text

Interferon beta-1b by Goodkin, D E

Get more information

Glucocorticosteroid therapy for multiple sclerosis: A critical review by Andersson, Peter-Brian, Goodkin, Donald E

“…Controversy remains as to the efficacy, route of administration and dose of glucocorticosteroid (GCS) in multiple sclerosis (MS) therapy. With the recent…”
Get full text